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Abstract: Rheumatoid arthritis (RA) is an autoimmune disease, characterized by chronic inflammation
of the joints with severe pain and swelling, joint damage and disability, which leads to joint destruction
and loss of function. Despite extensive research efforts, the underlying cause for RA is still unknown
and current therapies are more or less effective in controlling symptoms but still fail to cure the disease.
In recent years, epigenetic modifications were found to strongly contribute to the development of RA
by affecting diverse aspects of the disease and modifying gene expression levels and behavior of several
cell types, first and foremost joint resident synovial fibroblasts (SF). RASF are the most common cell
type at the site of invasion. Owing to their aggressive, intrinsically activated phenotype, RASF are active
contributors in joint damage. RASF are characterized by their ability to secrete cytokines, chemokines and
joint-damaging enzymes. Furthermore, these cells are resistant to apoptosis, leading to hyperplasia of the
synovium. In addition, RASF have invasive and migratory properties that could lead to spreading of the
disease to unaffected joints. Epigenetic modifications, including DNA methylation and post-translational
histone modifications, such as histone (de)acetylation, histone methylation and histone sumoylation were
identified as regulatory mechanisms in controlling aggressive cell activation in vitro and in disease outcome
in animal models in vivo. In the last 5 years, the field of epigenetics in RA has impressively increased.
In this review we consider the role of diverse epigenetic modifications in the development of RA, with a
special focus on epigenetic modifications in RASF.
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Rheumatoid arthritis (RA) is a chronic inﬂ ammatory 
disease aﬀ ecting about 1% of the population. Both genetic 
predisposition and environmental factors, as well as an 
aberrant activation of the innate and adapted immune 
sys tem, play a role in the pathogenesis. Th e major patho-
logical phenomena of RA are the massively elevated 
levels of inﬂ ammatory cytokines produced by activated B 
cells and T cells, as well as other cell populations and a 
synovial hyperplasia, resulting in damage of the cartilage 
and bone. Characteristically, peripheral joints are often 
aﬀ ected in a symmetric distribution. During active 
disease states, RA leads to swelling and pain, resulting in 
disability, joint destruction and, ultimately, loss of func-
tion. A number of characteristics – such as the occur-
rence of erosions at the time of presentation shortly after 
onset of symptoms, synovial inﬁ ltrates in clinically un-
aﬀ ected joints and the appearance of autoantibodies long 
before the onset of the disease – suggest that the disease 
develops long before clinical symptoms become apparent 
[1]. At least two subsets of RA exist, which are divided by 
the presence or absence of antibodies against citrullinated 
peptide antigens (ACPA). Th e presence or absence of 
ACPA has been proven one of the best clinical predictors 
for disease outcome. Recent genome-wide association 
studies suggested that ACPA-positive RA and ACPA-
negative RA also diﬀ er signiﬁ cantly in the frequency of 
risk alleles. Th e most important genetic risk factors 
account ing for 30 to 50% of the overall risk for RA are 
mainly conﬁ ned to the human leukocyte antigen locus 
[2].
In recent years, knowledge about pathogenic mecha-
nisms and treatment strategies in RA has signiﬁ cantly 
improved. Only one-third of patients respond well to the 
ﬁ rst-line treatment methotrexate [3], however, and 
although the application of biological drugs including 
thera peutic antibodies directed against TNFα is of great 
beneﬁ t for aﬀ ected patients, all currently available thera-
pies are more or less eﬀ ective in controlling symptoms 
and there is still a subgroup of nonresponding patients. 
No cure for the disease so far exists and the entire cause 
of the disease remains elusive.
In the last years, resident synovial ﬁ broblasts (SF) 
emerged as key players in the development of RA that 
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actively contribute to joint destruction. RASF are the 
most common cell type at sites of invasion. By implanting 
healthy human cartilage together with RASF into severe 
combined immunodeﬁ cient mice, Lefèvre and colleagues 
demonstrated that activated RASF migrate in vivo and 
spread the disease to sites of implanted cartilage. Whereas 
RASF actively degraded human cartilage, control im-
planted SF from osteoarthritis (OA) patients and dermal 
ﬁ broblasts from healthy donors did not. Since RASF were 
able to destroy cartilage even in the absence of cellular 
and humoral immune responses, this study revealed that 
RASF are capable of maintaining their activated pheno-
type without further stimulation of the inﬂ ammatory 
environment in the synovium [4]. RASF diﬀ er from 
healthy synovial ﬁ broblasts by their morphology and an 
aberrant gene expression pattern [5]. RASF are charac-
terized by the expression of antiapoptotic molecules, 
protooncogenes and a lack of expression of tumor 
suppressor genes. Owing to their ability to produce pro-
inﬂ ammatory cytokines and chemokines, RASF further 
attract inﬂ ammatory cells of the immune system to the 
synovium. In addition, RASF produce enzymes such as 
matrix metalloproteinases (MMPs) that promote invasion 
into and destruction of cartilage [5]. In recent years RASF 
were also characterized by aberrant epigenetic 
modiﬁ cations that might explain their intrinsic activated 
phenotype (Figure  1), and in the future they might 
provide the missing link between RA, risk factors and a 
lack of therapy response.
Originally, epigenetic modiﬁ cations were described as 
heritable alterations of gene expression or cellular pheno-
types that were caused by mechanisms other than changes 
in the DNA sequence. In a more revised deﬁ nition of 
epigenetics, also environmentally induced and shorter 
lived, reversible alterations of the histone code were 
included [6]. Epigenetic modiﬁ cations determine the 
stability of the chromatin structure, the genome integrity, 
the modulation of gene expression, embryonic develop-
ment, genomic imprinting and X-chromosome inactiva-
tion (XCI) in females [7]. Beside DNA methylation, large 
networks of post-translational modiﬁ cations on histone 
tails, such as acetylation, phosphorylation, methylation, 
ubiquitination or sumoylation, appear to represent 
diﬀ erent regulatory mechanisms of chromatin activity in 
several biological settings [8]. In this review we draw a 
detailed picture for the role of diverse epigenetic 
modiﬁ cations in the development of RA with a special 
focus on epigenetic modiﬁ cations in RASF.
DNA methylation
DNA methylation is the best understood epigenetic 
modi ﬁ cation and in general is associated with gene silen-
cing. DNA methylation is catalyzed by DNA methyl-
transferases (DNMTs) that use S-adenosyl-l-methionine 
as a methyl donor [7]. Th e predominant DNMT in 
somatic cells is DNMT1. In mammalian genomic DNA, 
position 5 of the cytosine residue within a cytosine-phos-
phate-guanine dinucleotide (CpG) motif is methylated, 
resulting in the formation of 5-methylcytosine [7]. 
Genomic DNA methylation is found throughout the 
genome. Most CpG islands, short CpG-rich regions, are 
generally unmethylated while the majority of CpG sites in 
non-CpG islands are methylated [9]. CpG islands are 
often located in the vicinity of transcription start sites of 
several genes [10], and the methylation status of these 
regulatory DNA sequences correlates with the transcrip-
tional activity of the corresponding genes [7].
Th e ﬁ ndings of an aberrant expression of normally 
silenced retrotransposable L1 elements in RA but not OA 
tissues, and their inducibility by treatment of cultured SF 
with the demethylating agent 5-aza-2’-deoxycytidine, 
suggest a functional role for DNA hypomethylation in 
the pathogenesis of RA [11]. Based on this ﬁ rst 
indication, members of our group detected a global DNA 
hypomethylation in RASF and RA tissues, and normal SF 
cultured in a hypomethylating milieu acquired an activa-
ted phenotype similar to RASF [12]. Th e global DNA 
hypomethylation was shown to be due to an increased 
polyamine metabolism in RASF, resulting in decreased 
levels of S-adenosyl-l-methionine [13]. Furthermore, the 
expression of DNMT1 protein was shown to be decreased, 
accompanied by an increased expression of the prolifera-
tion marker proliferating cell nuclear antigen, in RASF 
com pared with OASF [12]. A global DNA hypo methy-
lation was also shown in peripheral blood mononuclear 
cells (PBMC) derived from RA patients compared with 
healthy controls. In RA-derived PBMC, however, the 
mRNA expression levels of DNMT1 were increased [14]. 
Besides global changes of DNA methylation patterns in 
RA, hypomethylation of promoter regions of single 
genes, such as for chemokine (C-X-C motif ) ligand 12 
(CXCL-12) were reported [15]. Recent publications 
demon strated that even demethylation of a single CpG 
motif in the promoters of the IL-6 [16,17] and IL-10 
[18,19] genes correlated with their expression levels, and 
therefore contributed to elevated cytokine levels during 
disease. On the other hand, some DNA regions can also 
be hypermethylated in RA. Th e promoter region of the 
death receptor 3 gene (DR3), a member of the apoptosis 
inducing Fas gene family, was shown to be hyper methy-
lated in RA patients [20].
DNA methylation was also shown to regulate expres-
sion levels of miRNAs [21,22]. miRNAs are a class of 
short noncoding RNAs that function as post-translational 
repressors of gene expression by binding to the 3’ 
untranslated region of target genes. Th is leads to either 
degradation and/or inhibition of translation [23]. A 
screening of 260 individual miRNAs for diﬀ erential 
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expression in RASF and OASF revealed that an array of 
miRNAs is overexpressed in RASF. One of the most 
diﬀ erentially expressed miRNAs in RASF compared with 
OASF was miR-203. By treating RASF with the demethy-
lating agent 5-aza-2’-deoxycytidine, miR-203 expression 
was further induced. Overexpression of miR-203 in RASF 
resulted in an increased expression of MMP1 as well as 
increased IL-6 secretion rates [21]. One miRNA that is 
downregulated in RA and regulated by methylation of the 
promoter region is miR-34a*. Decreased expression of 
miR-34a* in RASF resulted in upregulation of its direct 
target X-linked inhibitor of apoptosis protein, and 
thereby contributed to the apoptosis resistant phenotype 
of RASF [22]. Th e future role of miRNAs in the 
pathogenesis of RA was recently reviewed by our 
laboratory [24].
Another study investigating the involvement of DNA 
methylation in the pathogenesis of RA came from a 
group investigating the silencing of the second X 
chromo some in females. Th is study revealed an increased 
presence of a skewed XCI pattern in RA patients. Instead 
of a random XCI, at least 80% of cells exhibited an 
inactivation of the same X chromosome [25]. Th ese data 
suggest a role for XCI mosaicism in the pathogenesis of 
RA and might be one of the explanations for why RA is 
more prevalent in women.
Histone acetylation and deacetylation
Th e best studied histone modiﬁ cations are the acetylation 
of speciﬁ c lysine residues of histones H3 and H4. Th ese 
modiﬁ cations play a fundamental role in transcriptional 
regulation but also other processes such as replication. 
Th e acetylation state of a chromatin region is tightly 
controlled by two antago niz ing enzyme families, namely 
histone acetylase trans ferases (HATs) and histone 
deacetylases (HDACs) [26]. Acetylation is generally 
associated with transcrip tional activation. HATs such as 
lysine acetyltransferase 2A (GCN5), lysine acetyl trans-
ferase 2B (PCAF), CREB binding protein, p300, and 
lysine acetyltransferase 8 (MOF) often function as trans-
criptional co-activators. On the contrary, deacetylation of 
chromatin is linked to gene silencing and HDACs were 
identiﬁ ed as trans crip tional co-repressors. In humans, 18 
HDACs have been identiﬁ ed and they are further 
Figure 1. Epigenetic modifi cations in rheumatoid arthritis synovial fi broblasts contribute to their aggressive phenotype. Rheumatoid 
arthritis synovial fi broblasts (RASF) are characterized by excessive activation and an apoptosis-resistant phenotype, leading to hyperplasia of the 
synovium. Furthermore, RASF are capable of producing chemokines and cytokines, and thereby promote infl ammation. The production of matrix 
metalloproteinases (MMPs) leads to invasion of RASF into cartilage. These characteristics of RASF contribute to the hallmarks of RA, namely joint 
destruction, loss of function, disability and pain. Changes in epigenetic modifi cations, such as DNA methylation, histone acetylation, histone 
methylation, and histone sumoylation, were described in pathologically activated RASF.
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subgrouped into four classes based on their orthologous 
homology to yeast (Table  1). Class I HDACs include 
HDAC1, HDAC2, HDAC3 and HDAC8, whereas the 
group of class II HDACs comprises HDAC4, HDAC5, 
HDAC6, HDAC7, HDAC9 and HDAC10. Th e seven 
sirtuins SIRT1 to SIRT7 build up the group of class III 
HDACs. HDAC11 is the only human enzyme classiﬁ ed as 
a class IV HDAC [26].
Most of the available data about the role of HDACs in 
the pathogenesis of RA were obtained using HDAC 
inhibitors (Table 1), ﬁ rst and foremost trichostatin A 
(TSA), an inhibitor of all class I and class II HDACs [27]. 
Th e lack of HDAC-speciﬁ c inhibitors makes the inter-
pretation of data diﬃ  cult. Furthermore, one must bear in 
mind that HATs and HDACs target not only histones but 
also other proteins including transcription factors such 
as NF-κB and signal transducer and activator of 
transcription 3. Th ese transcription factors also play key 
roles in inﬂ ammatory processes and are therefore also 
involved in pathogenic processes in RA.
TSA was shown to sensitize RASF for TNFα-related 
apoptosis-inducing ligand-induced apoptosis and to 
induce a cell cycle arrest by inducing the cell cycle 
regulator p21 [28]. A positive eﬀ ect of the HDAC inhi-
bitor FK228 on inhibiting RASF proliferation by induc-
tion of p21 and p16 promoter acetylation and expression 
was previously shown by Nishida and colleagues [29]. 
High doses of TSA and nicotinamide, a SIRT inhibitor, 
were also eﬀ ective in inducing apoptosis in RA macro-
phages [30]. HDAC inhibitors might thus positively 
inﬂ uence synovial hyperplasia in RA, on the one hand by 
inhibiting the activation of RASF and on the other by 
inducing apoptosis in macrophages.
Furthermore, these inhibitors also reduced the TNFα-
induced production of IL-6 and the lipopolysaccharide-
induced secretion of IL-6 and TNFα. Interestingly, the 
authors could not ﬁ nd a close association between the 
beneﬁ cial eﬀ ects of HDAC inhibitors on cytokine 
production and the overall HDAC inhibitor-dependent 
histone H3 and H4 acetylation [30]. Th ese results indicate 
that not all eﬀ ects of HDAC inhibitors are related to 
histone modiﬁ cations. Recently, Grabiec and colleagues 
identiﬁ ed one of the molecular mechanisms underlying 
the anti-inﬂ ammatory activity of HDAC inhibitors. Th e 
authors demonstrated that the HDAC inhibitors TSA 
and ITF2357 suppressed cytokine-induced and Toll-like 
receptor ligand-induced expression of IL-6 in RASF and 
macrophages by accelerating IL-6 mRNA decay. How-
ever, also other, not yet identiﬁ ed molecular mechanisms 
are involved in beneﬁ cial eﬀ ects of HDAC inhibitors in 
RA, since the authors also stated that reduced mRNA 
stability did not explain the suppressive eﬀ ects of 
cytokine-induced MMP1 and IL-8 expression in RASF 
[31].
Beneﬁ cial eﬀ ects of HDAC inhibitors have been 
demon strated in vivo by several groups using animal 
models of arthritis [29,32-35]. Since then, speciﬁ c HDAC 
inhibitors have been continuously discussed as potential 
thera peutics not only in cancer but also in RA. Systemic 
administration of the HDAC inhibitor FK228 reduced 
joint swelling, synovial inﬂ ammation and subsequent 
bone and cartilage destruction in a mouse model of 
autoantibody-mediated arthritis [29]. Th e prophylactic 
and therapeutic eﬀ ects of the HDAC inhibitors sub-
eroylanilide hydroxamic acid and MS-275 were addressed 
in collagen-induced arthritis in rats and mice. Th is study 
also led to the conclusion that HDAC inhibitors are an 
innovative therapeutic strategy for RA [32]. In the same 
model, a dose-dependent eﬀ ect of TSA was shown to 
reduce clinical signs of arthritis. Th e authors detected an 
increased number of cells with acetylated histone H4. 
Also, tissue inhibitor of MMP1 (TIMP1)-positive cells 
were increased, while the numbers of MMP3-positive 
and MMP13-positive chondrocytes were reduced as 
detected by immuno histochemical staining [33]. Further-
more, the HDAC inhibitor valproic acid signiﬁ cantly 
decreased disease incidence and severity in collagen-
induced arthritis mice. Th ese eﬀ ects were mediated by 
improving the production and function of CD25+FOXP3+ 
regulatory T cells, whose function is defective in RA 
patients [34].
Although much data on beneﬁ cial eﬀ ects of HDAC 
inhibitors have been reported, the role of individual 
HDACs in the development of RA and their functional 
role in SF have not been fully elucidated to date and are 
still a matter of debate. In analogy to the investigation of 
global changes of DNA methylation in RA tissues and 
RASF, research groups also aimed to verify potential 
global changes in histone acetylation in RA. Initially, 
diminished HDAC1 and HDAC2 expression and a 
reduced total HDAC activity were described in synovial 
tissues of RA compared with OA patients, implicating a 
shift towards histone hyperacetylation in patients with 
RA and pointing to a potential role of HDACs in the 
pathogenesis of RA [36]. Later, an increased expression 
of HDAC1 and HDAC2 in RASF compared with OASF 
was described. By silencing these enzymes in RASF, the 
authors could demonstrate a functional role of HDAC1 
and HDAC2 on proliferation and susceptibility to 
apoptosis [37].
Kawabata and colleagues also investigated the total 
HDAC activity in nuclear extracts of OA and RA tissues. 
Controversial to previous reports, in this study an 
increased HDAC activity and an unchanged HAT activity 
in RA tissues compared with OA tissues was reported. 
Furthermore, a decreased mRNA expression of HDAC4 
and an increased mRNA and protein expression of 
HDAC1 in RA tissues were shown. Interestingly, 
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stimu lation of RASF with TNFα speciﬁ cally increased 
total HDAC activity and the expression of HDAC1 [38], 
suggesting that changes in synovial HDAC activity and 
expression may be inﬂ uenced by the local inﬂ ammatory 
status [39].
A total increased HDAC activity was also reported 
recently in PBMC derived from RA patients, irrespective 
of whether or not patients were treated with the TNFα 
inhibitor etanercept. TSA and the HDAC3 selective 
inhibitor MI192 reduced lipopolysaccharide-stimulated 
cyto kine production in PBMC derived from healthy 
donors and RA patients in a cell-type and compound-
speciﬁ c manner [40]. Th e signiﬁ cance of studies analyz-
ing HDAC expression levels is currently quite unclear, 
since the environmental inﬂ uences that lead to the 
variability in HDAC expression and activity in synovial 
tissues are far from being understood.
At present, only few reports exist showing speciﬁ c 
changes in promoter histone acetylation in RA [29,41]. 
Stimulation of RASF with TNFα and IL-1β induced the 
promoter acetylation of the cell cycle regulator p21 and 
correlated with RASF proliferation [29]. Furthermore, 
the promoter region of MMP1 was shown to be hyper-
acetylated in RASF and the authors could show a 
functional role for HDAC4 in this mechanism (see below) 
[41], being in line with the results from Kawabata and 
colleagues reporting a reduced HDAC4 expression in RA 
tissues [38].
Th e functional role of SIRTs in RA has been rarely 
studied to date [30,42]. As already mentioned, Grabiec 
and colleagues showed a positive eﬀ ect of SIRT inhibitors 
in macrophages [30]. Recently, SIRT1 was reported to be 
overexpressed in RASF and monocytes derived from RA 
patients and expression levels of SIRT1 were further 
increased in the presence of TNFα. Overexpression of 
SIRT1 contributed to the apoptosis resistance in RASF 
and promoted the proinﬂ ammatory cytokine production 
in monocytes [42]. Th e functional role of other members 
of the SIRT family has not yet been studied.
Histone methylation
Data on the contribution of histone modiﬁ cations other 
than acetylation in the pathogenesis of RA are still rare, 
and the role of epigenetic methylation marks on lysine 
and/or arginine residues of histones is far less understood 
than the function of histone acetylation. Th e predominant 
histones modiﬁ ed by methylation are histones H3 and 
H4. Lysine residues can be monomethylated, dimethy-
lated or trimethylated, adding yet another layer of com-
plexity to this histone mark [8]. Depending on the 
methylated position, methylation of histones can be 
associated with more active or inactive chromatin regions. 
Th e trimethylation of histone 3 lysines H3K27m3, 
H3K9m3 and H4K20m3 are generally connected to 
trans criptionally silenced genes, whereas H3K36m3, 
H3K4m3 and H3K79m3 are associated with an open 
chromatin structure and transcriptionally active genes 
[43].
Our group addressed for the ﬁ rst time the role of 
histone methylation in RA and described an over-
expression of the histone methyltransferase enhancer of 
zeste homologue 2 (EZH2) in RASF compared with 
OASF. EZH2 is the catalytic subunit of the polycomb 
repressor complex 2 that adds up to three methyl marks 
to H3K27 of genes designated for silencing [44]. EZH2 
overexpression resulted in a reduced expression of the 
secreted frizzeled-related protein 1 (SFRP1), an inhibitor 
of the wingless-type MMTV integration site (Wnt) 
Table 1. Classifi cation of histone deacetylases and their inhibitors
Class Member Inhibitors References
I HDAC1 TSA, SAHA, ITF2357, FK228, VPA, MS-275 [27,40,47-51]
 HDAC2 TSA, SAHA, ITF2357, FK228, VPA 
 HDAC3 TSA, SAHA, ITF2357, FK228, VPA, MS-275, MI192 
 HDAC8 TSA, SAHA, ITF2357, FK228, VPA 
II HDAC4 TSA, SAHA, ITF2357, VPA [27,47,49,50]
 HDAC5 TSA, SAHA, ITF2357, VPA 
 HDAC6 TSA, SAHA, ITF2357, VPA 
 HDAC7  TSA, SAHA, ITF2357, VPA 
 HDAC9 TSA, SAHA, ITF2357, VPA 
 HDAC10 TSA, SAHA, ITF2357, VPA 
III SIRT1 to SIRT7 Nicotinamide [52]
IV HDAC11 – 
Human histone deacetylases (HDACs) were classifi ed into four subgroups. HDAC inhibitors summarized in the text are listed. SAHA, suberoylanilide hydroxamic acid; 
SIRT, sirtuin; TSA, trichostatin A; VPA, valproic acid.
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signaling pathway, which plays an important role in joint 
development and has been implicated in the pathogenesis 
of inﬂ ammatory arthropathies. However, the described 
mechanism seems to be speciﬁ c for SFRP1 and elevated 
EZH2 expression levels did not correlate with global 
changes in H3K27me3 in RASF [45].
Sumoylation
Another post-translational modiﬁ cation described in RA 
is sumoylation [46]. Members of our group showed that 
RASF have intrinsically high levels of the small ubiquitin-
like modiﬁ er 1 paralleled by decreased levels of its 
speciﬁ c protease SENP1. By overexpressing SENP1 in 
RASF, histone H4 acetylation in the MMP1 promoter 
was reduced, leading to a reduced invasiveness of RASF. 
Th e authors showed that SENP1 overexpression is also 
accompanied by a global reduction of histone H4 
acetylation and that the mechanism depends on the 
presence of HDAC4 [41].
Conclusions
Th ere is no doubt that epigenetic modiﬁ cations aﬀ ect 
RA. Several studies demonstrated that epigenetics contri-
bute to the aggressive, intrinsic activated phenotype of 
RASF and also the ﬁ rst in vivo data point to the beneﬁ cial 
eﬀ ects of drugs modifying epigenetic patterns in animal 
models. However, more data are needed to clarify which 
modiﬁ cations are causative for the disease onset and 
which epigenetic changes occur during chronic disease 
states. Whereas the picture of a diﬀ erential pattern of 
DNA methylation in RA becomes clearer, other 
epigenetic modiﬁ cations in RA have not yet been studied 
at all, or their functional role in the pathogenesis of RA is 
still puzzling. Understanding the complexity of diﬀ erent 
epigenetic modiﬁ cations that regulate gene expression in 
cooperation and understanding the inﬂ uence of environ-
mental factors and current therapies on epigenetic 
modiﬁ cations is just at the beginning. Th e available data 
raise the hope that, in future, detailed knowledge of 
epigenetic regulatory mechanisms in RA will help to 
develop new treatment strategies or will predict treat-
ment eﬃ  cacy and treatment outcome.
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